当前位置: X-MOL 学术Microbiologyopen › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis
MicrobiologyOpen ( IF 3.9 ) Pub Date : 2020-12-20 , DOI: 10.1002/mbo3.1148
Xianghai Zeng 1 , Pengfei She 1 , Linying Zhou 1 , Shijia Li 1 , Zubair Hussain 1 , Lihua Chen 1 , Yong Wu 1
Affiliation  

The bacterium Enterococcus faecalis has increasingly attracted global attention as an important opportunistic pathogen due to its ability to form biofilms that are known to increase drug resistance. However, there are still no effective antibiofilm drugs in clinical settings. Here, by drug repurposing, we investigated the antibacterial activity of penfluridol (PF), an oral long‐acting antipsychotic approved by the FDA, against E. faecalis type strain and its clinical isolates. It was found that PF inhibited the growth of E. faecalis planktonic cells with the MIC and MBC of 7.81 µg/ml and 15.63 ~ 62.50 µg/ml, respectively. Moreover, PF could significantly prevent the biofilm formation of E. faecalis at the concentration of 1 × MIC. Furthermore, PF significantly eradicated 24 h pre‐formed biofilms of E. faecalis in a dose‐dependent manner, with a concentration range of 1 × MIC to 8 × MIC. Here, through the checkerboard method with other tested conventional antibiotics, we also determined that gentamycin, penicillin G, and amikacin showed partial synergistic antibacterial effects with PF. Also, PF showed almost no hemolysis on human erythrocytes. In a mouse peritonitis model, a single dose of 20 mg/kg of PF treatment could significantly reduce the bacterial colonization in the liver (~5‐fold reduction) and spleen (~3‐fold reduction). In conclusion, these findings indicated that after structural optimization, PF has the potential as a new antibacterial agent against E. faecalis.

中文翻译:

药物再利用:五氟利多对粪肠球菌的抗菌和抗生物膜作用

肠球菌作为一种重要的机会性病原体越来越受到全球关注,因为它能够形成已知会增加耐药性的生物膜。然而,在临床环境中仍然没有有效的抗生物膜药物。在这里,通过药物再利用,我们研究了经 FDA 批准的口服长效抗精神病药物五氟利多 (PF) 对大肠杆菌的抗菌活性 粪肠球菌型菌株及其临床分离株。发现PF抑制E的生长。 粪浮游菌细胞的 MIC 和 MBC 分别为 7.81 µg/ml 和 15.63 ~ 62.50 µg/ml。此外,PF 可以显着阻止E的生物膜形成。.  粪菌浓度为 1 × MIC。此外,PF 显着消除了 24 小时内预先形成的大肠杆菌生物膜 粪便呈剂量依赖性,浓度范围为 1 × MIC 至 8 × MIC。在这里,通过棋盘法与其他测试的常规抗生素,我们还确定庆大霉素、青霉素 G 和阿米卡星与 PF 显示出部分协同抗菌作用。此外,PF对人红细胞几乎没有溶血。在小鼠腹膜炎模型中,单剂量 20 mg/kg PF 治疗可显着减少肝脏(减少约 5 倍)和脾脏(减少约 3 倍)中的细菌定植。总之,这些发现表明,经过结构优化后,PF 具有作为抗大肠杆菌的新抗菌剂的潜力 粪便
更新日期:2021-02-16
down
wechat
bug